Battle of GLP-1 delivery technologies

Advanced Drug Delivery Reviews
Minzhi YuAnna Schwendeman

Abstract

Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) belong to an important therapeutic class for treatment of type 2 diabetes. Six GLP-1 RAs, each utilizing a unique drug delivery strategy, are now approved by the Food and Drug Administration (FDA) and additional, novel GLP-1 RAs are still under development, making for a crowded marketplace and fierce competition among the manufacturers of these products. As rapid elimination is a major challenge for clinical application of GLP-1 RAs, various half-life extension strategies have been successfully employed including sequential modification, attachment of fatty-acid to peptide, fusion with human serum albumin, fusion with the fragment crystallizable (Fc) region of a monoclonal antibody, sustained drug delivery systems, and PEGylation. In this review, we discuss the scientific rationale of the various half-life extension strategies used for GLP-1 RA development. By analyzing and comparing different approved GLP-1 RAs and those in development, we focus on assessing how half-life extending strategies impact the pharmacokinetics, pharmacodynamics, safety, patient usability and ultimately, the commercial success of GLP-1 RA products. We also anticipate future GLP-1 RA development tre...Continue Reading

Citations

Apr 9, 2019·Expert Opinion on Emerging Drugs·Eun Ji ParkDong Hee Na
Mar 17, 2020·Diabetes, Obesity & Metabolism·Kun-Ho YoonChristopher H Sorli
Jul 4, 2020·Expert Opinion on Drug Delivery·Shuying WangW John Kao
Jan 4, 2020·The AAPS Journal·Chester E MarkwalterRobert K Prud'homme
Dec 16, 2018·Journal of Controlled Release : Official Journal of the Controlled Release Society·Camilla Kaas FrichAlexander N Zelikin
Oct 31, 2020·European Journal of Pharmaceutics and Biopharmaceutics : Official Journal of Arbeitsgemeinschaft Für Pharmazeutische Verfahrenstechnik E.V·Tinghui LiSteven P Schwendeman
Jan 24, 2021·Advanced Drug Delivery Reviews·Renjie LiuGregory A Hudalla
Jan 9, 2021·Journal of Controlled Release : Official Journal of the Controlled Release Society·Yanan WangZhiyu He
Jan 9, 2021·Signal Transduction and Targeted Therapy·Dehua YangMing-Wei Wang
Jul 4, 2020·Journal of Controlled Release : Official Journal of the Controlled Release Society·Seung Ho LeeYoung Bin Choy
May 21, 2021·International Journal of Pharmaceutics·Sonja KinnaMark E Welland
Jul 24, 2021·Diabetes Therapy : Research, Treatment and Education of Diabetes and Related Disorders·Kristina S BoyeLouis S Matza
Jul 28, 2021·Advanced Drug Delivery Reviews·Virender KumarRam I Mahato
Aug 29, 2021·Pharmaceutics·Alexander BenetAnna Schwendeman

❮ Previous
Next ❯

Related Concepts

Related Feeds

Cardiovascular Biology of GLP-1

Glucagon-like peptide 1 (GLP-1) plays a role in glucose metabolism, energy homeostasis, and inflammation suppression. GLP-1 receptor signaling has been shown to impact cardiovascular function. This feed focuses on the role of GLP-1 and GLP-1 receptor agonists on cardiovascular biology.

Related Papers

American Journal of Health-system Pharmacy : AJHP : Official Journal of the American Society of Health-System Pharmacists
Anne Ottney
Expert Opinion on Biological Therapy
Michael J Riedel, Timothy J Kieffer
© 2022 Meta ULC. All rights reserved